Borer Denton & Associates Inc. Grows Position in Becton, Dickinson and Company (NYSE:BDX)

Borer Denton & Associates Inc. raised its position in Becton, Dickinson and Company (NYSE:BDX) by 0.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 33,750 shares of the medical instruments supplier’s stock after buying an additional 70 shares during the quarter. Becton, Dickinson and Company makes up approximately 2.8% of Borer Denton & Associates Inc.’s portfolio, making the stock its 15th biggest position. Borer Denton & Associates Inc.’s holdings in Becton, Dickinson and Company were worth $8,137,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of BDX. Cetera Investment Advisers boosted its stake in Becton, Dickinson and Company by 380.8% during the 1st quarter. Cetera Investment Advisers now owns 58,923 shares of the medical instruments supplier’s stock worth $14,580,000 after purchasing an additional 46,668 shares during the period. M&G Plc boosted its stake in shares of Becton, Dickinson and Company by 0.9% during the second quarter. M&G Plc now owns 709,259 shares of the medical instruments supplier’s stock worth $165,967,000 after buying an additional 6,052 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 79.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after buying an additional 1,317,723 shares during the period. Benson Investment Management Company Inc. increased its position in Becton, Dickinson and Company by 13.2% in the 3rd quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock valued at $5,380,000 after acquiring an additional 2,602 shares during the period. Finally, Swedbank AB increased its position in Becton, Dickinson and Company by 1.8% in the 3rd quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock valued at $36,367,000 after acquiring an additional 2,729 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

BDX stock opened at $224.00 on Friday. The firm has a 50 day moving average of $235.15 and a 200-day moving average of $234.54. The company has a market cap of $64.74 billion, a price-to-earnings ratio of 37.71, a PEG ratio of 1.68 and a beta of 0.43. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.42 earnings per share. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be given a $1.04 dividend. The ex-dividend date is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.86%. Becton, Dickinson and Company’s payout ratio is currently 63.97%.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Evercore ISI lifted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $255.00 to $275.00 in a research report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Raymond James lowered their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $283.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.